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Abstract
HIV-1 can disseminate between susceptible cells by two mechanisms: cell-free infection fol-
lowing fluid-phase diffusion of virions and by highly-efficient direct cell-to-cell transmission
at immune cell contacts. The contribution of this hybrid spreading mechanism, which is also
a characteristic of some important computer worm outbreaks, to HIV-1 progression in vivo
remains unknown. Here we present a new mathematical model that explicitly incorporates
the ability of HIV-1 to use hybrid spreading mechanisms and evaluate the consequences for
HIV-1 pathogenenesis. The model captures the major phases of the HIV-1 infection course
of a cohort of treatment naive patients and also accurately predicts the results of the Short
Pulse Anti-Retroviral Therapy at Seroconversion (SPARTAC) trial. Using this model we find
that hybrid spreading is critical to seed and establish infection, and that cell-to-cell spread
and increased CD4+ T cell activation are important for HIV-1 progression. Notably, the
model predicts that cell-to-cell spread becomes increasingly effective as infection pro-
gresses and thus may present a considerable treatment barrier. Deriving predictions of vari-
ous treatments’ influence on HIV-1 progression highlights the importance of earlier
intervention and suggests that treatments effectively targeting cell-to-cell HIV-1 spread can
delay progression to AIDS. This study suggests that hybrid spreading is a fundamental fea-
ture of HIV infection, and provides the mathematical framework incorporating this feature
with which to evaluate future therapeutic strategies.
Author Summary
The ability to spread using more than one mechanism, named hybrid spreading, is a ubiq-
uitous feature of many real world epidemics including HIV and Hepatitis C virus infection
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Research and MRC grant MR/K012037 (PB); PB is ain vivo, and computer worms spreading on the Internet. Hybrid spreading of HIV is well
documented experimentally but its importance to HIV progression has been unclear. In
this paper, we introduce a mathematical model of HIV dynamics that explicitly incorpo-
rates hybrid spreading. The model output shows excellent agreement to two sets of clinical
data from a treatment naive cohort and from the Short Pulse Anti-Retroviral Therapy at
Seroconversion trial. The model demonstrates that hybrid spreading is an essential feature
of HIV progression, a result which has significant implications for future therapeutic strat-
egies against HIV.
Introduction
The course of HIV-1 infection is typified by three phases; acute infection characterized by a
rapid viraemia peak (3–6 weeks post-infection) followed by a rapid fall in virus levels, a stable
chronic phase of variable length characterized by low level viraemia and slowly declining CD4
+
T cell numbers, and a final stage (Acquired Immune Deficiency Syndrome, AIDS) character-
ized by multiple opportunistic infections and a rapid fall in CD4
+ T cell count. The cellular and
viral changes which drive each phase of this complex infection have been the subject of intense
debate, in which mathematical models have played an important role in delineating HIV-1
pathogenesis and informing antiretroviral therapy [1–3]. The rich literature appertaining to
mathematical modeling of intra host HIV dynamics has been reviewed several times recently
[1, 4–6]. Recent studies incorporate sophisticated models of immune selection [7, 8], as well as
the formation of a latent reservoir of quiescent infected cells [9, 10]. However the interplay of
cell-to-cell spread and increased CD4
+ T cell activation, that are likely to have profound influ-
ences on the progression of the disease have been hitherto little studied. Here we have ad-
dressed this and developed a unified model that can explain the complex progress of the
infection in all its phases and its variable timescale. Such a unified model is important not only
to understand the HIV-1 infection dynamics, but also to estimate the long term effects of thera-
peutic strategies on HIV-1 progression. In this paper, unless otherwise stated, “T cells” refers to
CD4
+ T cells.
HIV-1 predominantly replicates in CD4
+ T cells in vivo, and is now known to spread be-
tween T cells by two parallel routes. According to the classical model of HIV-1 spread, virus
particles bud from an infected T cell, enter the blood/extracellular fluid and then infect another
T cell following a chance encounter (termed cell-free spread). Because diffusion of virus parti-
cles is much faster than cell migration, and there is extensive flow of blood and fluid, this mode
of spreading can be characterized by a well mixed epidemic spreading model. In this scenario,
the probability of infection for a particular cell will be proportional to the concentration of ex-
tracellular infectious virus. However, HIV-1 can also disseminate by direct transmission from
one cell to another by a process of cell-to-cell spread. Two pathways of cell-to-cell transmission
have been reported. Firstly, an infected T cell can transmit virus directly to a target T cell via a
virological synapse [11–13]. Secondly, an antigen presenting cell (APC) can also transmit HIV-
1 to T cells by a process that either involves productive infection (in the case of macrophages)
or capture and transfer of virions in trans (in the case of dendritic cells) [11]. Whichever path-
way is used, infection by cell-to-cell transfer is reported to be much more efficient than cell-
free virus spread [14–16]. A number of factors contribute to this increased efficiency, including
polarised virus budding towards the site of cell-to-cell contact, close apposition of cells which
minimizes fluid-phase diffusion of virions, and clustering of HIV-1 entry receptors on the tar-
get cell to the contact zone [11, 12]. Cell-to-cell spread is thought to be particularly important
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+ T lymphocytes are densely packed and likely to frequently in-
teract. Indeed, intravital imaging studies have supported the concept of the HIV-1 virological
synapse in vivo [17, 18].
Hybrid spreading is in fact a feature of other viral infections [19], but is also shared in other
“epidemic” scenarios such as spread of computer worms [20, 21], or of mobile phone viruses
[22]. The mathematical analysis of hybrid spreading has received significant previous attention
[22–25]. However, the importance of hybrid spread to HIV-1 dissemination and disease pro-
gression, has not been explored from a mathematical point of view.
In this paper we develop a new mathematical model which incorporates the basic principles
of previous host-centric models including a virus-dependent immune response [8], viral laten-
cy and a progressive increase in cell activation [26, 27]. Notably, the model additionally in-
cludes explicit terms for the two modes of virus spread, parametrised from experimental
observation. The model faithfully replicates the overall three phase course of HIV-1 infection.
The model predictions are consistent with both a set of longitudinal data (viral load and CD4
+
T cell count) from a cohort of treatment naive HIV-1 infected patients and the results of the
Short Pulse Anti-Retroviral Therapy at Seroconversion (SPARTAC) trial that aims to evaluate
how the short-course antiretroviral therapy (ART) delays HIV progression [28]. The results of
our study reveal the importance of two modes of HIV-1 spread, highlight the close link be-
tween cell-to-cell spread and cell activation in driving the progression of HIV-1 infection to
AIDS and support early therapeutic intervention (i.e. “test-and-treat” initiatives) to delay dis-
ease progression in infected individuals. Since cell-to-cell spread is likely to present a consider-
able barrier to HIV-1 eradication, our data suggest that efforts to target this mode of viral
spread whilst simultaneously manipulating CD4
+ T cell activation may be a fruitful strategy to
help control virus infection and halt progression to AIDS.
Results
The HIV-1 model
We here introduce a model of HIV-1 infection as depicted in Fig. 1A. We consider four distinct
CD4
+ T cell states: activated, uninfected susceptible (S) cells; activated and productively in-
fected (I) cells; quiescent, uninfected (Q) cells; and quiescent latently (L) infected cells. The
total CD4
+ cell density (N) changes with time and is given by the sum of these four terms, i.e.
N(t)=Q(t)+S(t)+I(t)+L(t). The model can be described by an Ordinary Differential Equa-
tion (ODE) system (Equation 1) and is illustrated in Fig. 1A.
dQ
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Q þ b
dS
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¼  gSS   rSS þ a
NM
N
Q   cI
S
N
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N
L
dV
dt
¼  gVV þ gI
ð1Þ
The density variables (Q, S, I, L, V) and parameters are deﬁned in Table 1. The densities are
measured as numbers of cells or virions in a μl of blood/extracellular ﬂuid. We set a density var-
iable to zero when it drops to below 10
−12/μl, accounting for the fact that when density of cells
Hybrid Spreading of HIV
PLOS Computational Biology | DOI:10.1371/journal.pcbi.1004179 April 2, 2015 3 / 19or virions drops to such low level, there is a high probability that it would die out (density be-
comes zero). The default value of parameters, shown in Table 1, are taken from the literature
or estimated from clinical and experimentally observed data. The killing coefﬁcient κ equals to
its value in Table 1 when t   D; otherwise κ = 0 when t < D.
The production rate of new quiescent T cells from sources, such as thymus, within the
human body is represented by b. Quiescent T cells are activated and become susceptible at a
variable activation rate a(NM/N), where a is the activation coefficient and NM is the density of
T cells at which proliferation stops. The activation rate a(NM/N) increases as the total T cell
density (N) falls (caused by the HIV-1 progression). The detailed mechanism of how the activa-
tion rate increases with the progression of HIV-1 is still unclear, and may include increased
rates of co-infections, danger signals from dying T cells or homeostatic regulatory loops. This
term, a(NM/N), here is an approximation, which encompasses the combined effects of all these
different mechanisms. Quiescent T cells die at a rate of γ.
Fig 1. The HIV-1 model reproduces the full course of HIV-1 infection. (A) Diagrammatic representation of the model described by Equation 1.
(B) Numerical solutions of the model, plotting N, the density of all CD4
+ T cells (y axis on the left) and V, the density of free virions (y axis on the right in log
scale) as a function of time (in days or weeks), respectively. The initial infection starts on day 0 and the cellular immune response starts on day 30. Parameter
values are in Table 1.(C) The density of quiescent, susceptible, latent and infected CD4
+ T cells, and the density of free virions as function of time (in days).
doi:10.1371/journal.pcbi.1004179.g001
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(1 − N/NM), where p is the proliferation coefficient, N is the total T cell density, and NM is the
T cell density at which proliferation stops. This variable proliferation rate is a reasonable ap-
proximation [29] to the real T cell proliferation process, based on evidence [2] that T cell pro-
liferation rate is density-dependent and would slow as the T cell density becomes high.
Susceptible T cells die at a rate γS.
Susceptible T cells become infected through both cell-to-cell and cell-free infection. For cell-
free infection, the number of newly infected T cells per unit period of time is β2 SV, where β2 is
the infection rate of susceptible T cells by free virus. For cell-to-cell infection, we consider that
the T cells are randomly moving, i.e. a T cell has an equal chance of contacting any other T
cells. Let c represent the number of effective contacts each T cell makes in a unit period of time.
Table 1. Variables and parameters of our model.
Variables Initial value Unit
Q Density of quiescent CD4
+ T cells
a Q0 = 708 cells/μl
S Density of susceptible CD4
+ T cells
a S0 =1 7 cells/μl
I Density of infected CD4
+ T cells I0 =0 cells/μl
L Density of latent CD4
+ T cells L0 =0 cells/μl
N Density of all CD4
+ T cells N0 = 725 cells/μl
V Density of free HIV-1 virus V0 =1 0
−6 virions/μl
Parameters Default value Unit Reference
γ Death rate of quiescent and latent cells 0.001 /day [29]
γS Death rate of susceptible cells 0.0625 /day [30]
γI Death rate of infected cells 0.5 /day [29]
b Production rate of new quiescent cells
b 0.17 cells/μl/day [31]
rS Resting rate of susceptible cells 0.5 /day
rI Resting rate of infected cells 0.0001 /day
a Cell activation coefﬁcient 0.01 /day
p Cell proliferation coefﬁcient 1 /day [29]
NM Cell threshold density
c 800 cells/μl
g Virus release rate from an infected cell 100 virions/cell/day [29]
γV Virus death rate 3 /day [29, 31]
c Cell contact rate
d 330 /day [14, 32, 33]
θ Cell synapse rate
e 0.56 [12, 14, 32, 34]
β1 Cell-to-cell infection rate
f 0.19 [15, 33, 35, 36]
β2 Cell-free infection rate 0.00135 μl/virions/day [29]
D Immune response delay
g 30 days [37]
κ Killing coefﬁcient (when t ≽ D)
h 1.5 /day
a Q0 and S0 are chosen to maintain a stable density of CD4
+ T cells (N0 = 725 cell/μl) in the absence of an infection;
b Production from sources including thymus;
c Beyond this threshold CD4
+ T cell proliferation stops;
d The average number of effective contacts between two CD4
+ T cells. Cells contact each other frequently, but only a proportion (20–25%) of these
random contacts are sufﬁciently stable and “effective” for a synapse to be formed at rate θ;
e The average probability to form a virological synapse when two cells have an effective contact;
f The average probability that a susceptible cell is infected when it forms a synapse with an infected cell;
g Between the initial infection and the onset of cellular immune response, including the period before symptoms begin;
h κ = 0 when t < D.
doi:10.1371/journal.pcbi.1004179.t001
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those contacts, S/N are contacts with a susceptible T cell that could potentially end up with a
new infection. Let θ represent the Synapse rate: the average probability that two T cells form a
virological synapse once they have made an effective contact. Then the number of newly in-
fected T cells through cell-to-cell infection per unit time period can be represented as cI(S/N)
θβ1, where β1 is the cell-to-cell infection rate when an infected T cell and a susceptible T cell
form a synapse. In reality, cell-to-cell transfer occurs locally involving only the infected cell and
its immediate neighbours. The model abstracts this process by averaging infection over all
cells. In practice, local effects will only distort this average when target cells in the vicinity of an
infected cell become limiting. This limit seems unlikely to be reached except very late in infec-
tion, given that infected cells continue to migrate, albeit at a slower rate (personal observations
and [17]), and uninfected target cells continue to migrate into the vicinity of an infected cell.
More complex spatial models will be required, however, to understand the detailed anatomical
distribution of HIV-1 infected cells over time. The amount of cell-to-cell transfer in the model
depends on the number of infected T cells I and the proportion of susceptible cells S/N at any
given time. Since N, the total density of CD4
+ cells, is not held constant, but in fact declines
over time, cell-to-cell spread becomes increasingly effective as HIV-1 progresses.
The model does not explicitly distinguish antigen-presenting cell to T cell (APC/T) from T
cell to T cell (T/T) transmission. APC/T transmission may potentially be most important very
early in establishing infection [38], a process which is not examined in detail in this model.
These two types of transmission are in fact both likely to occur most frequently and efficiently
in the microenvironment of an APC/T cluster, where APC/T interactions lead to T cell activa-
tion, and hence favour also T/T interaction. Furthermore, there are very few quantitative esti-
mates of the parameters of APC/T interaction in vivo. The incorporation of an additional cell
type is therefore unlikely to have a major effect on the model behaviour, but would add signifi-
cantly to model complexity and uncertainty.
The cause of T cell death in HIV-1 infection continues to be controversial, and probably in-
cludes several effects including lysis of infected cells by effector cells such as CD8 T cells and
NK cells, apoptosis/pyroptosis and bystander death [27]. Non-immunological death of infected
T cells is represented by a death rate of γI. And we use the term k
I
Iþ0:1
N
NM to model the death of
infected T cells by the cellular immune response. κ is initially 0 and changes to a higher value
in Table 1 when the cellular immune response kicks in D (default value: 30) days after the ini-
tial infection. The term
I
Iþ0:1 captures the relationship between the strength of the immune re-
sponse and the density of infected CD4
+ T cells [8]. The term N/NM captures immune
exhaustion caused by HIV-1 infection. It falls from around 1 before infection towards 0 as
HIV-1 progresses (because NM is a constant and N, the total density of CD4
+ T cells, gradually
declines with the HIV-1 progression).
Infected cells return to a quiescent state, and become latent, at rate rI. Latent cells die and
are activated (i.e. becomes infected cells) at the same rates as quiescent cells. Infected T cells re-
lease free viruses at rate g. Free viruses die at a rate of γV.
The abortive infection of quiescent cells is not considered in this simplified model, similarly
to most previous modelling studies [1, 3, 39, 40]. HIV-1 immune escape mutants [41] are not
directly modelled in this paper but their effects on degrading cellular immune response are re-
flected in the immune exhaustion in our model.
The numerical solutions of each of the variables are shown in Fig. 1C. Fig. 1B shows the
combined CD4
+ T cell counts (N) and virus load (V), which are measured routinely in the clin-
ic to monitor HIV-1 infection. Notably, the qualitative behaviour of the model accurately re-
flects the three main phases of disease that are observed clinically. The model reproduces an
Hybrid Spreading of HIV
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ing adaptive immunity), peaks and then returns to a low level by approximately 5 weeks. This
metastable level of virus represents the clinical “set-point”. Virus then remains stable for a pro-
longed period (note interruption and change of scale in x axis), during which time T cells de-
cline very slowly. Finally, T cell numbers start to drop faster, and viral loads rise. The model
calculation is stopped when CD4
+ level reaches 200 cells/μl.
It is important to note that the term cI(S/N)θβ1 we introduced for cell-to-cell spread is
mathematically different from the classic term β2 SV which captures cell-free spread. N, the
total CD4
+ number, is not a constant but decreases as a function of time. Indeed, if N in the
cell-to-cell spread term is fixed, disease progression is not observed in the model (S1 Fig). Fur-
thermore, N cannot be expressed as a simple function of V.I nFig. 1B the same value of V (free
virion density) on each side of its peak around t = 30 days corresponds to two different N
(CD4
+ T cell density) values. In addition, I, the number of infected cells, is not always propor-
tional to V, especially early in infection (S2 Fig). Thus the term for cell-to-cell spread cI(S/N)
θβ1 shows different dynamics from the classic cell-free term β2 SV.
Model evaluation
Most of the parameters of our model, and especially those determining HIV infectivity via cell-
to-cell or cell-free spreading, were obtained from experimental observations (Table 1). It was
therefore important to test that the model with this parametrization accurately fits real clinical
data sets. We therefore evaluated our model against a set of longitudinal T cell count and virus
load measurements obtained from a cohort of HIV-1-infected individuals who were recruited
following clinical presentation with symptomatic acute HIV-1 infection and followed over
time with serial measurement of plasma viral RNA levels and circulating T cell counts. The
subjects selected for inclusion in this study all chose not to receive antiretroviral treatment in
acute or early infection, and remained untreated until progression towards AIDS, evidenced by
a substantial decline in their circulating CD4
+ T cell count (See Materials and Methods).
We use our model to theoretically reproduce the HIV-1 infection courses in the data. The
values for HIV infectivity were fixed, as derived from the literature or our own observations
(Table 1). Values for five parameters (Q0, S0, NM, κ and D) describing the characteristics of the
immune response were chosen for each patient to minimise the error of the predicted quasi-
stable level of T cell counts (Ns) and viral load (Vs), and the time of progression to AIDS (tA).
All other values remained fixed at the default values in Table 1. The predicted progression re-
sults are compared against the actual measurements in Fig. 2 and S2 Table. The predicted Vs
and tA for each patient were negatively correlated (correlation coefficient = −0.46), in agree-
ment with the well-established relationship between these two clinical values. Remarkably, the
model can fit all patients by modifying the five immune-relevant parameters over a narrow
range. Furthermore, the parameter values which gave the best results for the patients (see S1
Table) are all very close to those in Table 1, which were derived independently from
experimental measurements.
The importance of cell-to-cell spread and cellular activation
Having confirmed that the model gives realistic estimations and predictions of real clinical
data, we investigated the behaviour of the model in more detail. The role of the two spreading
routes was further examined by systematic variation of the cell-to-cell infection rate, β1, and
the cell-free infection rate, β2. The predicted outcome of infection are shown in Fig. 3. When ei-
ther route is abolished, infection is blocked completely; T cell level returns to normal and virus
is cleared after the cellular immune response kicks in. If cell-to-cell spread is removed from the
Hybrid Spreading of HIV
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model prediction (diamond) for the time to AIDS (tA), the quasi-steady density of CD4
+ T cells (Ns) and the quasi-steady density of free virions (Vs). An arrow
represents that tA is greater than a particular value (represented by the connected circle) for a patient as his / her CD4
+ count did not reached AIDS level (200
cells/μl) in the data.(B) Prediction (curve) of HIV progression course (N and log10 V) for four typical patients, where clinical data are shown as dots.Full
prediction results are shown in S1 Table and S2 Table.
doi:10.1371/journal.pcbi.1004179.g002
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sion. In contrast, a doubling of cell-to-cell infection rate increases the set-point of viral load,
and greatly speeds up the progression of infection even in the absence of cell-free infectivity.
Thus the model suggests cell-to-cell spread may be an important force in allowing virus to es-
tablish infection in lymphoid tissue [38].
In the context of the model, the transition from phase 1 (acute) to phase 2 (stable chronic) is
driven by a balance between several processes, including viral spreading through two parallel
modes, and the cellular immune response, i.e. killing of infected cells as the cytotoxic CD8
+ T
cell response becomes active. Paradoxically, in the stable chronic phase, the activation of T
cells, which is the hallmark of adaptive immunity and is aimed at protecting the host, in fact
contributes to the persistence of HIV-1. The role of CD4
+ T cell activation is explored in
Fig. 4A. In this model, the rate of T cell activation a(NM/N) increases as the number (N)o fT
cells falls, which can be considered to represent a type of homeostatic regulation reinforcing
immunological activity relevant to the progressive damage of the immune system and its con-
sequences. In the absence of this feedback (i.e. when activation rate is fixed), HIV infection
would not progress to AIDS after the onset of the cellular immune response. In contrast, if the
activation rate is doubled, then infection progresses significantly faster to AIDS. These results
confirm and extend the findings of DeBoer and Perelson [29], which suggested an increasing
rate of cellular activation was important in establishment of chronic infection and progression
to AIDS. The results are also consistent with evidence that non-pathogenic SIV infection in the
natural host species results in viral replication in the absence of chronic immune activation
and no AIDS [42]. Fig. 4B depicts the number of CD4
+ T cells newly infected via either cell-to-
cell spread or cell-free spread as the infection progresses. The model predicts that cell-to-cell
Fig 3. Two modes of HIV-1 infection. The density of CD4
+ T cells as a function of time for different values of cell-to-cell infection rate β1 and cell-free
infection rate β2: (1) both use their default value, (2) β1 uses its default value and β2 = 0, (3) β1 = 0 and β2 uses its default value, (4) β1 is twice its default value
and β2 = 0, (5) β1 = 0 and β2 is twice its default value.
doi:10.1371/journal.pcbi.1004179.g003
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+ T cells falls, the propor-
tion of susceptible cells rises (Fig. 4B inset left y axis) and the strength of immune response falls
(because of immune exhaustion, see Fig. 4B inset right y axis).
Treatment evaluation
Modelling can help evaluate the long term effects of different treatments on HIV-1 progression.
Once the start time, duration, and effectiveness against two modes of HIV-1 spread are known
for a treatment, its effects on HIV-1 progression can be evaluated by the model.
To validate the model’s ability to evaluate HIV-1 treatments, we use it to theoretically repro-
duce the results of the Short Pulse Anti-Retroviral Therapy at Seroconversion (SPARTAC)
trial [28]. The SPARTAC trial aims to evaluate how the short-course antiretroviral therapy
(ART) delays HIV progression. The patients (366 in total) who participated in the trial were
randomly assigned to three groups: standard care, 12-week ART treatment, and 48-week ART
treatment. For these three groups of patients, the primary end point tp (defined as when CD4
+
count   350 cells/μl or the start of long-term ART) on average reached 157 weeks (standard
care), 184 weeks (12-week ART), and 222 weeks (48-week ART) after randomisation. Rando-
misation is the time when the trial starts.
We first estimate the trial time points (randomisation, start of the treatments, and primary
end points tp) in terms of days after the initial infection (See Materials and Methods). We then
use the average CD4
+ count and virus load of all patients at randomisation, and the primary
end point of the patients in standard care group to fit the five immune-relevant model parame-
ters (Q0, S0, NM, κ and D). These fitted parameters represent an average patient in the trial.
We then evaluated the effects of 12 and 48 week therapy using the model. We assumed that
the therapy was 100% effective against cell-free transmission, but we evaluated the model for
both 100% and 50% efficiency against cell-to-cell transmission, since cell-to-cell transmission
has been reported as being more resistant to some forms of therapy [43, 44]. Both modalities
reproduced the observed effects of therapy well, and the model results were robust to changes
in the efficiency (Table 2). The model therefore not only fits known data sets (standard care
Fig 4. Progressive CD4
+ T cell activation drives progression to AIDS and increased cell-to-cell infection. (A) Progression of HIV-1 infection for
different cell activation rates, including (1) normal activation (aNM/N in Equation 1), (2) fixed activation (aNM/N0, where N0 is the initial density of CD4
+ T cells),
and (3) doubled activation (2 × aNM/N when t > D).(B) Numbers of newly infected cells in a day via cell-to-cell spreading and cell-free spreading, respectively.
The inset shows the ratio of susceptible cells to all cells (S/N, left y axis) and the strength of immune response (k
I
Iþ0:1
N
NM, right y axis) as a function of
time, respectively.
doi:10.1371/journal.pcbi.1004179.g004
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patient groups (12-week and 48-week).
We therefore further explored the sensitivity of the model to perturbation as a function of
treatment starting time (Fig. 5). The “treatment” lasts for 30 days, during which both cell-free
and cell-to-cell infection are completely blocked. Once “treatment” is finished, two modes of
HIV-1 infection resume. Early treatment in this model (3 days after infection, i.e. post-
Table 2. Model prediction of the SPARTAC trial.
Patient groups: Standard-care 12-week-treatment 48-week-treatment
Nr (cells/μl) Data: 559
Model: 560
Vr (virons/μl) Data: 17 (log10 Vr = 1.2)
Model: 12 (log10 Vr = 1.1)
tp (days) Data: 1,197 1,386 1,652
Model: 1,197 1,392 j 1,394 1,654 j 1,656
Nr and Vr are the density of CD4
+ T cells and free virions at randomisation (when patients groups are randomly divided and the trial starts). tp is the time
between the initial infection and the primary end point (when density of CD4
+ T cells decreases to 350 cells/μl or the start of long-term ART [28]). The tp
estimated from the model is the time when CD4
+ T cells decreases to 350 cells/μl. The Materials and Methods section describes how tp is inferred from
the data [28] in terms of days after infection. The model parameters calibrated from the trial data (by ﬁtting the average Nr, Vr for all patients and tp for the
standard care group) are Q0 = 566 cells/μl, S0 =1 3cells/μl, NM = 638 cells/μl, κ = 1.292165 /day and D =2 8days. The model predictions use the same Nr
and Vr for all three patient groups, which are the average of all patients in the trial. The trial treatment is assumed to be 100% effective against cell-free
HIV-1 spread. We estimate the tp for 12-week and 48-week treatment groups if the treatment is 50% (value in bold font) or 100% (value in normal font)
effective against cell-to-cell spread of HIV-1.
doi:10.1371/journal.pcbi.1004179.t002
Fig 5. Impact of treatment starting time on HIV progression. HIV progression for a 30-day ‘perfect’ treatment starting at three different times after the
initial infection: (1) on the 3rd day when the density of all CD4
+ T cells is N = 725 cells/μl, (2) when N = 500 cells/μl; (3) when N = 350 cells/μl. The ‘prefect’
treatment here means both cell-to-cell infection and the cell-free infection are completely blocked (i.e. β1 =0 ,β2 = 0 and the virus release rate g = 0) for
30 days.
doi:10.1371/journal.pcbi.1004179.g005
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+ T cell density, and no chronic infection
phase. The same treatment applied when T cell density reaches the levels (500 CD4
+ T cells/μl
and 350 CD4
+ T cells/μl) at which the World Health Organization recommends ART initiation
[45] is followed by a rapid virus rebound after the treatment stops, and the disease progresses
according to its normal course. Thus, as HIV-1 progresses it becomes increasingly difficult to
control infection in this model.
Finally, we looked at the interactions between treatment starting time, activation rate and ef-
ficiency of therapy against cell-to-cell spread (Fig. 6). In general, increased efficiency of therapy
and earlier treatment both prolonged time to progression to AIDS. However, the effects of al-
tered activation depend in a complex way on the context of the intervention. Blocking activa-
tion early is beneficial, since it will reduce the number of susceptible cells HIV-1 can infect;
while blocking activation late, when the latent HIV-1 reservoir has been established, will pre-
vent latent HIV-1 from being activated and eradicated. Increasing cellular activation, which
has been proposed as a means of flushing out the latent reservoir [46], can be effective in in-
creasing time to AIDS when given in the context of efficient anti-viral therapy, but can shorten
the time if concomitant anti-viral therapy is incomplete. This is because increasing cellular acti-
vation increases both the number of susceptible cells (activated from quiescent cells) and the
number of infected cells (activated from latent cells) at the same time. Thus if it is used together
with an effective anti-viral therapy, the latent HIV-1 reservoir will be flushed out and killed by
the antiviral drugs. But if the concomitant anti-viral therapy is not efficient enough to clear the
increased number of infected cells, the spread of HIV-1 will speed up.
Discussion
The aim of this study was to develop a model that reduces the enormous biological complexity
of the course of HIV-1 infection to a few well-defined equations but nevertheless retains the
main dynamic features of the disease. In particular, the model was required to predict the evo-
lution of a long lived metastable state of low level viral infection, which ultimately breaks down
to uncontrolled viral growth and a precipitous fall in CD4
+ T cells, two hallmarks of AIDS. The
model incorporates both an immune response, which is believed to be a major factor limiting
viral expansion by killing of infected cells, and the formation of long lived latently infected
cells, which are believed to play an important role in limiting the long-term effects of antiviral
therapy. The key distinguishing features of the model are that it incorporates explicitly
Fig 6. Prediction of the time to AIDS, tA, for different treatment schemes. We consider 30-day treatments starting (A) on the 3rd day and (B) when
N = 500 cells/μl, respectively. All treatments block cell-free infection completely (β2 = 0 and g = 0). The treatments also affect cell-to-cell infection (x axis) and
/ or manipulate the CD4
+ T cell activation process (y axis, see Fig. 4A). The black squares represent treatments that reduced the density of infected cells,
latent cells and free virions all below 10
−12 per μl.
doi:10.1371/journal.pcbi.1004179.g006
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ing such a model was to investigate the role of these two modes of spread in determining the
outcome of infection, and thus complement the limited in vivo experimental and clinical data
available addressing this question.
A fundamental prediction of the model is that, given the known experimentally derived pa-
rameters of cell-to-cell and cell-free spreading, the two modes of spread complement each
other and both make important contributions to disease progression. In addition, it is clear
that there is a close relationship between the proportion of activated T cells, cell-to-cell spread
and disease progression. Specifically, cell-to-cell spreading is strong when the percentage of ac-
tivated, and therefore susceptible cells is high in the population, since an infected cell is then
more likely to encounter an effective target (a susceptible cell) to infect. When the percentage
of susceptible cells is low, infected cells will mostly encounter quiescent/resting cells that will
provide ineffective targets. These conditions may occur both early and late in HIV-1 infection.
The site of infection itself (for example the vaginal mucosa) may contain a large proportion of
activated T cells some of which may be interacting with APC, particularly if there is a concomi-
tant sexually transmitted infection. The well-documented association between HIV-1 infection
and other mucosal infections may therefore reflect the key importance of a high concentration
of APC and activated T cells in early transmission of virus [47]. There is also convincing evi-
dence that gut associated lymphoid tissue is a major site of viral replication early on in disease
[48, 49]. This tissue is characterized by an unusually large proportion of T cells capable of sup-
porting HIV-1 replication, presumed to result from chronic exposure to the gut microbiome.
Since cell-to-cell spread is much more efficient, and under these conditions the number of acti-
vated target cells are not limiting, our model predicts that gut lymphoid tissue would provide
an ideal microenvironment for rapid propagation of HIV-1, at least until the majority of target
cells are infected or die. Further development of the basic model, to allow heterogeneity associ-
ated with different anatomical compartments would allow this prediction to be tested directly.
The model also predicts a dominant role for cell-to-cell spread in the late phase of HIV-1.
As in the scenario early in infection in the gut lymphoid tissue, our model predicts that late
stage disease will be associated with a large number of infected cells, combined with a large pro-
portion of activated target cells. A high number of infected cells is a simple corollary of the very
high levels of free virus late in infection in the absence of treatment. There is also substantial
experimental evidence for increased immune activation in the late phases of HIV-1 [26], and
indeed this has been proposed as an important contribution to pathogenesis. Thus cell-to-cell
spread is likely to become the dominant mode of transmission in the late stages of HIV-1. This
may be important in light of recent data showing that the different components of current
HAART display variable efficacy against cell-to-cell spread [43, 44].
Interestingly, the hybrid spreading mechanism employed by HIV-1 is reminiscent of those of
some computer worms such as Red Code II and Cornficker [20, 21],which allocate their re-
sources between probing for susceptible target computers in local area networks and globally
across the internet. Similarly to HIV-1, local interactions have a high chance of success but access
only a limited number of targets while global spread targets a much larger number of targets with
a much lower probability of success. Modelling studies have shown that thishybrid spreading is
required toexplainthelargeoutbreak ofsuchworms on the Internet [25].Itistemptingtospecu-
late that hybrid spreading may contribute to the pathogenicity and dynamics of infection of
other viruses that employ parrallel spreading mechanisms, for example Hepatitis C virus [19].
The current model incorporates some simplifying assumptions. Nevertheless, the model
does provide some insights into the effectiveness of therapy at different stages of disease. Spe-
cifically, the model strongly supports the hypothesis that interfering with viral infection early
in HIV-1 progression is likely to have a major impact on the subsequent progress of the disease.
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HIV-1 infection. The clinical decision about when to start therapy remains a matter of debate.
Current WHO guidelines suggest commencing treatment at CD4
+ T cell density of >
350cells/μl and < 500cells/μl [45]. However, studies exploring much earlier commencements
of treatment, have claimed increased efficacy [28, 50]. For example, the recent “Short Pulse
Anti-Retroviral Therapy at Seroconversion” (SPARTAC) trial, demonstrated a long term clini-
cal benefit of a limited period of ART soon after seroconversion [28]. Our model accurately
predicted the results of the SPARTAC trial providing further support for the model’s generality
and robustness.
Anti-viral therapies that specifically target cell-to-cell spread are not currently available, but
are clearly important therapeutic goals [44]. A number of previous studies have proposed com-
bining antiviral therapies with therapies that either limit CD4+ T cell activation (thus reducing
the number of target susceptible cells) or increased T cell activation, thus flushing out residual
latent cells. These approaches have not given clear cut clinical benefits [51, 52]. Indeed our
model suggests that the outcome of such manipulation of cellular activation will be critically
dependent on the time at which it is administered, and the efficiency of concomitant antiviral
therapy. Targeted suppression of CD4
+ T cell activation, in combination with antiviral thera-
pies may nevertheless offer a useful approach, if used early on in infection.
Mathematical models provide an important tool for understanding and predicting the
course of natural HIV-1 infection that complements clinical studies. The most appropriate
therapeutic regimens for HIV therapy continue to remain the subject of disagreement and de-
bate. In addition, many new therapeutic modalities aimed at achieving viral eradication, such
as the HDAC inhibitors [46], or therapeutic vaccination [53] are being proposed. However,
testing new treatment regimens is a costly and time consuming task, and the logistic challenges
and expense of running clinical trials to evaluate and compare treatments remain a major bot-
tleneck to translational advances in HIV therapy. Mathematical models have proved of value
in the past, but have suffered from omitting important biological processes, thus compromising
their ability to accurately recapitulate clinical observations. Our model explicitly incorporates
cell-to-cell transmission, and changing rates of cellular activation, two processes that are
known to be a key feature of HIV infection. With increased sophistication, and hence ability to
accurately model the known biological drivers of disease progression, mathematical models
can become increasingly important in preclinical testing of modified or novel HIV therapies.
The model developed here provides specific predictions which emerge from the close links be-
tween CD4
+ T cell activation and cell-to-cell spread, and their combined contribution to both
early and late phases of HIV-1. These predictions emphasize the potential benefits of early or
prophylactic treatment with antiretroviral therapies, and suggest that drugs with the ability to
effectively block cell-to-cell spread may provide significant therapeutic benefit in long term
management or eradication of HIV-1 infection.
Materials and Methods
Recruitment and follow-up of HIV-1 infected patients (London data)
Individuals acutely-infected with HIV-1 were recruited at the Mortimer Market Centre for Sex-
ual Health and HIV Research (London, UK). Subjects were mostly male Caucasians who pre-
sented with symptoms of acute retroviral illness. Patient viral loads and CD4
+ T cell counts
were measured longitudinally at serial time-points following infection using standard clinical
tests. All subjects were offered anti-retroviral treatment at diagnosis. The subjects selected for
inclusion in the study all chose not to receive anti-retroviral therapy in acute or early infection,
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circulating CD4
+ T cell count occurred.
Ethics statement
Patients provided written informed consent for study participation. Study approval was ob-
tained from The National Health Service Camden and Islington Community Local Research
Ethics Committee.
Selection of patients to be included in the study (London data)
There were 39 patients in total in the data from Mortimer Market Centre for Sexual Health
and HIV Research (London, UK). For this study, we focused our analysis only on patients with
more than ten data points for both HIV load and CD4
+ measurements (29 out of the 39 pa-
tients). We also excluded from the analysis a further 12 patients who showed no overall de-
crease in CD4
+ count, or no increase in viral load at later timepoints. The focus of the model
described above is to capture the “typical” characteristics of HIV infection, which include that
CD4
+ count falls in general, and viral load increases in general as infection progresses. It is
widely accepted that in some patients (for example the so-called “elite controllers”) viral load
remains low or undetectable and CD4
+ count remains unchanged for long periods. The mecha-
nisms responsible for these phenomena are still incompletely understood. The current model
does not attempt to incorporate any such mechanism, and this group of patients was therefore
not included in the study. Further elaboration of the current model to include additional fea-
tures of viral control will be informative in helping to understand such patients. The identifiers
for the remaining 17 patients are: MM1, MM4, MM8, MM9, MM12, MM13, MM23, MM24,
MM27, MM33, MM39, MM40, MM42, MM43, MM45, MM57, MM60.
Estimation of the time points of the SPARTAC trial
According to [28], the median interval between seroconversion and randomization (start of
trial) was 12 weeks. The exact average time of seroconversion for patients in the SPARTAC
trial is not directly available from [28]. We assume it is 2 weeks after initial infection, as sero-
conversion normally happens within a few weeks after HIV-1 infection. Then the time of ran-
domization (start of trial) can be estimated as 7(2 + 12) = 98 days after infection. The
treatment is estimated to start 3 days after randomization [28], i.e. 98 + 3 = 101 days after infec-
tion. And the primary end points for patients in standard care, 12-week ART, and 48-week
ART groups are respectively: 98 + 7 × 157 = 1197 days, 98 + 7 × 184 = 1386 days, and
98 + 7 × 222 = 1652 days after infection.
Availability and implementation
Calculation results in this paper are obtained using LeoTask [54], a parallel task running and
results aggregation framework that we have developed for computational research. The frame-
work and an executable programme that implements our HIV-1 model are both freely available
at http://github.com/mleoking/leotaskapp.
Supporting Information
S1 Table. Model parameters calibrated from a cohort of treatment-naive HIV-1 patients.
Results are shown for all 17 patients. In the data, time is recorded relative to the first appear-
ance of symptoms of HIV infection. As the actual initial infection date is unknown, we
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of symptoms.
(PDF)
S2 Table. Model prediction of a cohort of treatment-naive HIV-1 patients. NS is the quasi-
steady CD4
+ T cell density and VS is the quasi-steady density of free virions, which are average
densities between the 100th and 800th days after initial infection. tA is the time to AIDS, which
is defined as the time between initial infection and when the density of CD4
+ T cells falls to 200
cells/μl.
(PDF)
S1 Fig. HIV-1 infection course generated by the HIV-1 model using two different cell-to-
cell infection terms. 1) the normal cell-to-cell infection term (cθβ1 IS/N)i nEquation 1, and 2)
the cell-to-cell infection term that fixes N to be N0 (cθβ1 IS/N0 where N0 is the total number of
CD4
+ T cells before HIV-1 infection and it is a constant). With a fixed N = N0 in the term, the
HIV-1 model would not be able to recapitulate the AIDS phase.
(TIFF)
S2 Fig. V/I (density of free virions divided by the density of infected CD4
+ T cells) as a func-
tion of time. There are some obvious changes in V/I during the early days of HIV-1 infection.
The figure however also supports some existing works’ [8] assumption that V and I are propor-
tional to each other during the chronic (stable) phrase of HIV-1 infection. Our model depicts
HIV-1 infection in all its three phrases and we do not therefore assume V to be proportional to
I.
(TIFF)
Acknowledgments
We are extremely grateful to the patients who provided samples from which the data modelled
in this study was derived.
Author Contributions
Conceived and designed the experiments: CZ SZ CJ BMC. Performed the experiments: CZ EG
PP IW PB. Analyzed the data: CZ SZ BMC CJ. Contributed reagents/materials/analysis tools:
IW PB. Wrote the paper: CZ SZ PB BMC CJ.
References
1. Perelson AS, Ribeiro RM (2013) Modeling the within-host dynamics of hiv infection. BMC Biol 11: 96.
doi: 10.1186/1741-7007-11-96 PMID: 24020860
2. Ho DD, Neumann AU, Perelson AS, Chen W, Leonard JM, et al. (1995) Rapid turnover of plasma viri-
ons and CD4 lymphocytes in HIV-1 infection. Nature 373: 123–126. doi: 10.1038/373123a0 PMID:
7816094
3. Perelson AS, Neumann AU, Markowitz M, Leonard JM, Ho DD (1996) Hiv-1 dynamics in vivo: Virion
clearance rate, infected cell life-span, and viral generation time. Science 271: 1582–1586. doi: 10.
1126/science.271.5255.1582 PMID: 8599114
4. Prague M, Commenges D, Thiebaut R (2013) Dynamical models of biomarkers and clinical progression
for personalized medicine: The HIV context. Adv Drug Deliv Rev 65: 954–965. doi: 10.1016/j.addr.
2013.04.004 PMID: 23603207
5. Xiao Y, Miao H, Tang S, Wu H (2013) Modeling antiretroviral drug responses for HIV-1 infected patients
using differential equation models. Adv Drug Deliv Rev 65: 940–953. doi: 10.1016/j.addr.2013.04.005
PMID: 23603208
6. Alizon S, Magnus C (2012) Modelling the course of an HIV infection: Insights from ecology and evolu-
tion. Viruses 4: 1984–2013. doi: 10.3390/v4101984 PMID: 23202449
Hybrid Spreading of HIV
PLOS Computational Biology | DOI:10.1371/journal.pcbi.1004179 April 2, 2015 16 / 197. Elemans M, Florins A, Willems L, Asquith B (2014) Rates of CTL killing in persistent viral infection in
vivo. PLoS Comput Biol 10: e1003534. doi: 10.1371/journal.pcbi.1003534
8. Deutekom HWMv, Wijnker G, Boer RJ (2013) The rate of immune escape vanishes when multiple im-
mune responses control an HIV infection. J Immunol 191: 3277–3286. doi: 10.4049/jimmunol.1300962
PMID: 23940274
9. Rong L, Perelson AS (2009) Modeling latently infected cell activation: Viral and latent reservoir persis-
tence, and viral blips in hiv-infected patients on potent therapy. PLoS Comput Biol 5: e1000533. doi:
10.1371/journal.pcbi.1000533
10. Spina CA, Anderson J, Archin NM, Bosque A, Chan J, et al. (2013) An in-depth comparison of latent
HIV-1 reactivation in multiple cell model systems and resting CD4+ t cells from aviremic patients. PLoS
Pathog 9: e1003834.
11. Sattentau Q (2008) Avoiding the void: cell-to-cell spread of human viruses. Nat Rev Microbiol 6: 815–
826. doi: 10.1038/nrmicro1972 PMID: 18923409
12. Jolly C, Kashefi K, Hollinshead M, Sattentau QJ (2004) HIV-1 cell to cell transfer across an env-in-
duced, actin-dependent synapse. J Exp Med 199: 283–293. doi: 10.1084/jem.20030648 PMID:
14734528
13. Komarova NL, Levy DN, Wodarz D (2013) Synaptic transmission and the susceptibility of HIV infection
to anti-viral drugs. Sci Rep 3. doi: 10.1038/srep02103 PMID: 23811684
14. Martin N, Welsch S, Jolly C, Briggs JAG, Vaux D, et al. (2010) Virological synapse-mediated spread of
human immunodeficiency virus type 1 between T cells is sensitive to entry inhibition. J Virol 84: 3516–
3527. doi: 10.1128/JVI.02651-09 PMID: 20089656
15. Sourisseau M, Sol-Foulon N, Porrot F, Blanchet F, Schwartz O (2007) Inefficient human immunodefi-
ciency virus replication in mobile lymphocytes. J Virol 81: 1000–1012. doi: 10.1128/JVI.01629-06
PMID: 17079292
16. Duncan CJA, Russell RA, Sattentau QJ (2013) High multiplicity HIV-1 cell-to-cell transmission from
macrophages to CD4+ t cells limits antiretroviral efficacy. AIDS 27: 2201–2206. doi: 10.1097/QAD.
0b013e3283632ec4 PMID: 24005480
17. Murooka TT, Deruaz M, Marangoni F, Vrbanac VD, Seung E, et al. (2012) HIV-infected T cells are mi-
gratory vehicles for viral dissemination. Nature 490: 283–287. doi: 10.1038/nature11398 PMID:
22854780
18. Sewald X, Gonzalez DG, Haberman AM, Mothes W (2012) In vivo imaging of virological synapses. Nat
Commun 3: 1320. doi: 10.1038/ncomms2338 PMID: 23271654
19. Zeisel MB, Felmlee DJ, Baumert TF (2013) Hepatitis C virus entry. Curr Top Microbiol Immunol 369:
87–112. PMID: 23463198
20. Moore D, Shannon C, Claffy K (2002) Code-red: a case study on the spread and victims of an internet
worm. In: Proceedings of ACM SIGCOMM Workshop on Internet measurment. ACM, pp. 273–284.
doi:10.1145/637201.637244
21. Zhang C, Zhou S, Chain BM (2014). Hybrid epidemics - a case study on computer worm conficker. Pre-
print. Available: arXiv:1406.6046. Accessed 10 Feb 2015.
22. Wang P, Gonzalez MC, Hidalgo CA, Barabasi AL (2009) Understanding the spreading patterns of mo-
bile phone viruses. Science 324: 1071–1076. doi: 10.1126/science.1167053 PMID: 19342553
23. Keeling MJ, Danon L, Vernon MC, House TA (2010) Individual identity and movement networks for dis-
ease metapopulations. Proc Natl Acad Sci USA 107: 8866–8870. doi: 10.1073/pnas.1000416107
PMID: 20421468
24. Balcan D, Vespignani A (2011) Phase transitions in contagion processes mediated by recurrent mobili-
ty patterns. Nat Phys 7: 581–586. doi: 10.1038/nphys1944 PMID: 21799702
25. Zhang C, Zhou S, Cox IJ, Chain BM (2014). Optimizing hybrid spreading in metapopulations. Preprint.
Available: arXiv: 1409.7291. Accessed 10 Feb 2015.
26. Miedema F, Hazenberg MD, Tesselaar K, Baarle Dv, de Boer RJ, et al. (2013) Immune activation and
collateral damage in AIDS pathogenesis. Front Immunol 4: 298. doi: 10.3389/fimmu.2013.00298
PMID: 24133492
27. Doitsh G, Galloway NLK, Geng X, Yang Z, Monroe KM, et al. (2014) Cell death by pyroptosis drives
CD4 T-cell depletion in HIV-1 infection. Nature 505: 509–514. doi: 10.1038/nature12940 PMID:
24356306
28. Fidler S, Porter K, Ewings F, Frater J, Ramjee G, et al. (2013) Short-course antiretroviral therapy in pri-
mary HIV infection. N Engl J Med 368: 207–217. doi: 10.1056/NEJMoa1110039 PMID: 23323897
29. De Boer R, Perelson A (1998) Target cell limited and immune control models of HIV infection: A com-
parison. J Theor Biol 190: 201–214. doi: 10.1006/jtbi.1997.0548 PMID: 9514649
Hybrid Spreading of HIV
PLOS Computational Biology | DOI:10.1371/journal.pcbi.1004179 April 2, 2015 17 / 1930. Mohri H, Perelson AS, Tung K, Ribeiro RM, Ramratnam B, et al. (2001) Increased turnover of T lympho-
cytes in HIV-1 infection and its reduction by antiretroviral therapy. J Exp Med 194: 1277–1287. doi: 10.
1084/jem.194.9.1277 PMID: 11696593
31. Stafford MA, Corey L, Cao Y, Daar ES, Ho DD, et al. (2000) Modeling plasmavirus concentration during
primary HIV infection. J Theor Biol 203: 285–301. doi: 10.1006/jtbi.2000.1076 PMID: 10716909
32. Jolly C, Mitar I, Sattentau QJ (2007) Requirement for an intact T-cell actin and tubulin cytoskeleton for
efficient assembly and spread of human immunodeficiency virus type 1. J Virol 81: 5547–5560. doi: 10.
1128/JVI.01469-06 PMID: 17360745
33. Jolly C, Booth NJ, Neil SJD (2010) Cell-cell spread of human immunodeficiency virus type 1 overcomes
tetherin/bst-2-mediated restriction in T cells. J Virol 84: 12185–12199. doi: 10.1128/JVI.01447-10
PMID: 20861257
34. Hübner W, McNerney GP, Chen P, Dale BM, Gordon RE, et al. (2009) Quantitative 3D video microsco-
py of HIV transfer across T cell virological synapses. Science 323: 1743–1747. doi: 10.1126/science.
1167525
35. Chen P, Hübner W, Spinelli MA, Chen BK (2007) Predominant mode of human immunodeficiency virus
transfer between T cells is mediated by sustained env-dependent neutralization-resistant virological
synapses. J Virol 81: 12582–12595. doi: 10.1128/JVI.00381-07 PMID: 17728240
36. Del Portillo A, Tripodi J, Najfeld V, Wodarz D, Levy DN, et al. (2011) Multiploid inheritance of HIV-1 dur-
ing cell-to-cell infection. J Virol 85: 7169–7176. doi: 10.1128/JVI.00231-11 PMID: 21543479
37. McMichael AJ, Borrow P, Tomaras GD, Goonetilleke N, Haynes BF (2010) The immune response dur-
ing acute HIV-1 infection: clues for vaccine development. Nat Rev Immunol 10: 11–23. doi: 10.1038/
nri2674 PMID: 20010788
38. Parrish NF, Gao F, Li H, Giorgi EE, Barbian HJ, et al. (2013) Phenotypic properties of transmitted found-
er HIV-1. Proc Natl Acad Sci USA 110: 6626–6633. doi: 10.1073/pnas.1304288110 PMID: 23542380
39. Komarova NL, Wodarz D (2013) Virus dynamics in the presence of synaptic transmission. Math Biosci
242: 161–171. doi: 10.1016/j.mbs.2013.01.003 PMID: 23357287
40. Komarova NL, Anghelina D, Voznesensky I, Benjamin T, Levy DN, et al. (2013) Relative contribution of
free-virus and synaptic transmission to the spread of HIV-1 through target cell populations. Biol Lett 9.
doi: 10.1098/rsbl.2012.1049 PMID: 23269844
41. Fryer HR, Frater J, Duda A, Roberts MG, Phillips RE, et al. (2010) Modelling the evolution and spread
of HIV immune escape mutants. PLoS Pathog 6: e1001196. doi: 10.1371/journal.ppat.1001196
42. Silvestri G, Paiardini M, Pandrea I, Lederman MM, Sodora DL (2007) Understanding the benign nature
of SIV infection in natural hosts. J Clin Invest 117: 3148–3154. doi: 10.1172/JCI33034 PMID:
17975656
43. Sigal A, Kim JT, Balazs AB, Dekel E, Mayo A, et al. (2011) Cell-to-cell spread of HIV permits ongoing
replication despite antiretroviral therapy. Nature 477: 95–98. doi: 10.1038/nature10347 PMID:
21849975
44. Titanji BK, Aasa-Chapman M, Pillay D, Jolly C (2013) Protease inhibitors effectively block cell-to-cell
spread of HIV-1 between T cells. Retrovirology 10: 161. doi: 10.1186/1742-4690-10-161
45. WHO (2013). Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV
infection. URL http://www.who.int/hiv/pub/guidelines/arv2013/download/en/index.html.
46. Wightman F, Ellenberg P, Churchill M, Lewin SR (2012) HDAC inhibitors in HIV. Immunol Cell Biol 90:
47–54. doi: 10.1038/icb.2011.95 PMID: 22083528
47. Ward H, Ronn M (2010) Contribution of sexually transmitted infections to the sexual transmission of
HIV. Curr Opin HIV AIDS 5: 305–310. doi: 10.1097/COH.0b013e32833a8844 PMID: 20543605
48. Brenchley JM, Schacker TW, Ruff LE, Price DA, Taylor JH, et al. (2004) CD4+ T cell depletion during
all stages of HIV disease occurs predominantly in the gastrointestinal tract. J Exp Med 200: 749–759.
doi: 10.1084/jem.20040874 PMID: 15365096
49. Veazey RS, DeMaria M, Chalifoux LV, Shvetz DE, Pauley DR, et al. (1998) Gastrointestinal tract as a
major site of CD4+ T cell depletion and viral replication in SIV infection. Science 280: 427–431. doi: 10.
1126/science.280.5362.427 PMID: 9545219
50. Sáez-Ciríon A, Bacchus C, Hocqueloux L, Avettand-Fenoel V, Girault I, et al. (2013) Post-treatment
HIV-1 controllers with a long-term virological remission after the interruption of early initiated antiretrovi-
ral therapy anrs visconti study. PLoS Pathog 9: e1003211. doi: 10.1371/journal.ppat.1003211
51. Rizzardi GP, Harari A, Capiluppi B, Tambussi G, Ellefsen K, et al. (2002) Treatment of primary HIV-1 in-
fection with cyclosporin A coupled with highly active antiretroviral therapy. J Clin Invest 109: 681–688.
doi: 10.1172/JCI14522 PMID: 11877476
Hybrid Spreading of HIV
PLOS Computational Biology | DOI:10.1371/journal.pcbi.1004179 April 2, 2015 18 / 1952. Lederman MM, Smeaton L, Smith KY, Rodriguez B, Pu M, et al. (2006) Cyclosporin A provides no sus-
tained immunologic benefit to persons with chronic HIV-1 infection starting suppressive antiretroviral
therapy: results of a randomized, controlled trial of the AIDS clinical trials group a5138. J Infect Dis
194: 1677–1685. doi: 10.1086/509261 PMID: 17109339
53. Lu W, Arraes LC, Ferreira WT, Andrieu JM (2004) Therapeutic dendritic-cell vaccine for chronic HIV-1
infection. Nat Med 10: 1359–1365. doi: 10.1038/nm1147 PMID: 15568033
54. Zhang C, Zhou S, Chain BM (2015). LeoTask: a fast, flexible and reliable framework for computational
research. Preprint. Available: arXiv:1501.01678. Accessed 10 Feb 2015.
Hybrid Spreading of HIV
PLOS Computational Biology | DOI:10.1371/journal.pcbi.1004179 April 2, 2015 19 / 19